There are many obstacles to the success of a clinical trial and duplicate research subjects, or professional research subjects are unfortunately one of them. Duplicate subjects in clinical trials results in a myriad of poor outcomes. Ultimately duplicate research subjects can result in a clinical trial failing to meet its endpoints. And now with decentralized …
Interest in decentralized clinical trials has increased and has become quite popular. The adoption of these methods became acutely more appealing and necessary during the pandemic. Many research sites and clinical trial sponsors have adopted decentralized clinical trial methods. But decentralized clinical trials also come with unique challenges. To keep clinical trials safe, compliant, and effective, …
Clinical trials rely upon speed and accuracy to deliver new drugs and medicines to the public. Limiting the potential for unwanted variables that can skew the data is critical. One of these issues is professional research subjects or duplicate subjects in clinical trials. These particular participants often times have motives to partiicapte in the particular …
Clinical research patients are compensated for their participation in clinical trials. In some therapeutic areas and types of clinical trials, the compensation for enrolling in one or more clinical trials or at multiple research sites is enough to influence patients to join more than one contemporaneously and expose themselves to multiple investigational products or multiple …
Duplicate subjects, or what is known as professional research subjects, exist in most clinical trials to varying degrees. CNS clinical trials are especially prone to duplicate subjects or over enrollment in clinical tials. The issue exists from phase 1 healthy volunteer studies to multiple phase 2/3 clinical trials across many therapeutic indications. Use of global …
A quick look at some screening data in 3 close European countries demonstrates how research subjects travel to screen concurrently at multiple different sites. Professional research subjects often travel large distances between states or countries to do so. Some travel is within the same country to different sites, but there is significant travel between countries. …
We have seen tremendous progress within the clinical trials research industry in understanding the scope of the issue with duplicate subjects in clinical trials or professional research subjects over the past few years. Verified Clinical Trials (VCT) provides an easy to implement cost-savings approach to prevent duplicate subjects and other important protocol violations in your …
Several premier research centers in Germany have led the initiative and joined the global Verified Clinical Trials (VCT) research subject database registry to prevent duplicate subjects and other important protocol violations in an effort to improve safety and data quality in their clinical trials. Key research sites in Germany join Verified Clinical Trials to prevent …
Verified Clinical Trials (VCT) the leading global research subject database registry has teamed up with the STARR Coalition to create Project RockSTARR. The initiative allows sponsors to have research subjects that screen for a clinical trial donate a pre-allocated amount of money to local advocacy group of their choice. Advocacy and duplicate subject prevention in …
Without a “tool” such as the Verified Clinical Trials (VCT) global research subjects database registry, detecting duplicate subjects and protocol violations based upon prior study history or prior study drug (IP) exposure is impossible. VCT proactively detects these issues at the time of screening before costly screening procedures occur. The protections continue the entire duration …
